CAR-T-38

CAR-T-38 is a **chimeric antigen receptor (CAR) T-cell therapy** engineered to target **CD38**, a transmembrane glycoprotein highly expressed on most acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia in blastic phase (CML-BP), and multiple myeloma (MM) cells, but with limited expression on normal hematopoietic stem cells[1][4][7]. The CAR construct for CAR-T-38 uses an anti-CD38 single-chain variable fragment (scFv), coupled to CD3ζ and 4-1BB (or similar) co-stimulatory signals to activate T-cell effector function upon binding to CD38-expressing malignant cells[1]. The therapy has demonstrated preclinical and early clinical activity in patients with relapsed AML (especially after allogeneic stem cell transplantation), relapsed/refractory MM, T-ALL, and CML-BP, including those resistant to multiple lines of chemotherapy and targeted agents[4][7][10]. Early clinical trials (notably NCT04351022) report robust in vitro cytotoxicity and in vivo eradication of disease in some patients, with manageable adverse events primarily consisting of cytokine release syndrome[7][10]. CAR-T-38 aims to overcome the limits of conventional anti-CD38 monoclonal antibodies (such as daratumumab) by providing deeper and more sustained remissions through cellular immunotherapy[1][4][7].

Other names

CD38-targeted CAR-T cellCD-38-targeted CAR-T cellCD 38-targeted CAR-T cellCD38-redirected CAR-T cellCD-38-redirected CAR-T cellCD 38-redirected CAR-T cellCD38-directed chimeric antigen receptor T cellCD-38-directed chimeric antigen receptor T cellCD 38-directed chimeric antigen receptor T cell